Abstract:In recent years, with advancements in medicine, the survival period of patients with tumours has significantly increased. The adverse effects of tumour treatment on patients, especially cardiac toxicity, have become increasingly prominent. In elderly patients with breast cancer, treatment-related cardiovascular toxicity has surpassed cancer itself as the leading cause of death. Moreover, in recent years, an increasing number of novel antitumour drugs, such as multitargeted agents, antibody‒drug conjugates (ADCs), and immunotherapies, have been applied in clinical practice. The cardiotoxicity induced by these drugs has become more pronounced, leading to a complex and diverse mechanism of cardiac damage. The risks of unintended cardiovascular toxicity are increased by high-dose anthracyclines, immunotherapies, and concurrent radiation, in addition to traditional cardiovascular risk factors such as smoking, hypertension, diabetes, hyperlipidaemia, and obesity. However, these factors do not fully explain why only a subset of individuals experience treatment-related cardiac toxicity, whereas others with similar clinical features do not. Recent studies indicate that genetics play a significant role in susceptibility to the development of cardiovascular toxicity from cancer therapies. These genes are involved in drug metabolism, oxidative damage, cardiac dysfunction, and other processes. Moreover, emerging evidence suggests that epigenetics also plays a role in drug-induced cardiovascular toxicity. We conducted a review focusing on breast cancer as an example to help oncologists and cardiologists better understand the mechanisms and effects of genetic factors on cardiac toxicity. In this review, we specifically address the relationship between genetic alterations and cardiac toxicity, including chemotherapy-related genetic changes, targeted therapy-related genetic changes, and immune therapy-related genetic changes. We also discuss the role of epigenetic factors in cardiac toxicity. We hope that this review will improve the risk stratification of patients and enable therapeutic interventions that mitigate these unintended adverse consequences of life-saving cancer treatments.

Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions

Genetic Susceptibility and Mechanisms Underlying the Pathogenesis of Anthracycline-Associated Cardiotoxicity

Anthracycline Cardiotoxicity: From Mechanisms to Prevention Strategies

[Cardiotoxicity of drugs used in oncology]

Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms, Clinical Management and Innovative Treatment

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy

Anthracycline Chemotherapy and Cardiotoxicity

Research Progress on the Mechanism, Monitoring, and Prevention of Cardiac Injury Caused by Antineoplastic Drugs—Anthracyclines

Research progress of cardiotoxicity induced by chemotherapeutic drugs

Cardiac Complications of Chemotherapy: Role of Prevention

Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity

Genetic factors in the pathogenesis of cardio-oncology

Mechanisms of Myocardial Toxicity of Antitumor Drugs and Potential Therapeutic Strategies: A Review of the Literature

Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery

Mechanisms and Genetic Susceptibility of Chemotherapy-Induced Cardiotoxicity in Patients With Breast Cancer

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Research progress on cardio-protective drug for preventing anthracycline cardiotoxicity

Antineoplastic Therapies Related Cardiotoxicity

Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery

Chemotherapy-induced cardiotoxicity: a new perspective on the role of Digoxin, ATG7 activators, Resveratrol, and herbal drugs